Literature DB >> 19597016

Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

Jean Philippe Arnault, Janine Wechsler, Bernard Escudier, Alain Spatz, Gorana Tomasic, Vincent Sibaud, Selim Aractingi, Jean-Didier Grange, Vichnou Poirier-Colame, David Malka, Jean-Charles Soria, Christine Mateus, Caroline Robert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19597016     DOI： 10.1200/JCO.2009.23.4823

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  45 in total

Review 1.  Cutaneous side effects of new antitumor drugs: clinical features and management.

Authors:  Ralf Gutzmer; Andreas Wollenberg; Selma Ugurel; Bernhard Homey; Arnold Ganser; Alexander Kapp
Journal:  Dtsch Arztebl Int       Date:  2012-02-24       Impact factor: 5.594

2.  Drug discovery: inhibitors that activate.

Authors:  Karen Cichowski; Pasi A Jänne
Journal:  Nature       Date:  2010-03-18       Impact factor: 49.962

3.  Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.

Authors:  James A Fagin; R Michael Tuttle; David G Pfister
Journal:  J Clin Endocrinol Metab       Date:  2010-06       Impact factor: 5.958

4.  Resolution of lung adenocarcinoma after discontinuation of ibrutinib.

Authors:  Tamer Khashab; Sanam Loghavi; Sergej N Konoplev; Felipe Samaniego
Journal:  BMJ Case Rep       Date:  2016-07-18

5.  RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.

Authors:  Patrick A Oberholzer; Damien Kee; Piotr Dziunycz; Antje Sucker; Nyam Kamsukom; Robert Jones; Christine Roden; Clinton J Chalk; Kristin Ardlie; Emanuele Palescandolo; Adriano Piris; Laura E MacConaill; Caroline Robert; Günther F L Hofbauer; Grant A McArthur; Dirk Schadendorf; Levi A Garraway
Journal:  J Clin Oncol       Date:  2011-11-07       Impact factor: 44.544

6.  Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.

Authors:  Daniela Matei; Michael W Sill; Heather A Lankes; Koen DeGeest; Robert E Bristow; David Mutch; S Diane Yamada; David Cohn; Valerie Calvert; John Farley; Emanuel F Petricoin; Michael J Birrer
Journal:  J Clin Oncol       Date:  2010-11-22       Impact factor: 44.544

Review 7.  Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.

Authors:  Maria Vastarella; Gabriella Fabbrocini; Vincent Sibaud
Journal:  Drug Saf       Date:  2020-05       Impact factor: 5.606

8.  Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK.

Authors:  Harina Vin; Grace Ching; Sandra S Ojeda; Charles H Adelmann; Vida Chitsazzadeh; David W Dwyer; Haiching Ma; Karin Ehrenreiter; Manuela Baccarini; Rosamaria Ruggieri; Jonathan L Curry; Ana M Ciurea; Madeleine Duvic; Naifa L Busaidy; Nizar M Tannir; Kenneth Y Tsai
Journal:  Mol Cancer Ther       Date:  2013-10-29       Impact factor: 6.261

9.  [Cutaneous side effects of medical tumor therapy].

Authors:  A Degen; M Alter; F Schenck; A Kapp; R Gutzmer
Journal:  Hautarzt       Date:  2011-06       Impact factor: 0.751

10.  Analysis of dermatologic events in vemurafenib-treated patients with melanoma.

Authors:  Mario E Lacouture; Madeleine Duvic; Axel Hauschild; Victor G Prieto; Caroline Robert; Dirk Schadendorf; Caroline C Kim; Christopher J McCormack; Patricia L Myskowski; Olivia Spleiss; Kerstin Trunzer; Fei Su; Betty Nelson; Keith B Nolop; Joseph F Grippo; Richard J Lee; Matthew J Klimek; James L Troy; Andrew K Joe
Journal:  Oncologist       Date:  2013-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.